Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use

Japan’s first PCSK9 inhibitor Repatha (evolocumab) went on sale in the country on April 21, a day after it was added to the NHI reimbursement price list, Amgen Astellas BioPharma and Astellas Pharma said. The drug, which will be promoted...read more